New England Research & Management Inc. Sells 9,400 Shares of AstraZeneca plc (AZN)

New England Research & Management Inc. reduced its position in shares of AstraZeneca plc (NYSE:AZN) by 55.9% during the fourth quarter, HoldingsChannel reports. The firm owned 7,407 shares of the company’s stock after selling 9,400 shares during the quarter. New England Research & Management Inc.’s holdings in AstraZeneca were worth $257,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Fulton Bank N.A. lifted its position in shares of AstraZeneca by 85.6% during the fourth quarter. Fulton Bank N.A. now owns 79,666 shares of the company’s stock worth $2,764,000 after purchasing an additional 36,750 shares in the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of AstraZeneca by 11.6% during the third quarter. Parametric Portfolio Associates LLC now owns 1,790,092 shares of the company’s stock worth $60,648,000 after purchasing an additional 186,457 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of AstraZeneca during the third quarter worth $478,000. Belpointe Asset Management LLC acquired a new position in shares of AstraZeneca during the third quarter worth $309,000. Finally, Wealthcare Advisory Partners LLC bought a new stake in shares of AstraZeneca in the third quarter worth $184,000. 14.75% of the stock is currently owned by institutional investors and hedge funds.

Shares of AstraZeneca plc (AZN) opened at $35.47 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. AstraZeneca plc has a 12 month low of $26.51 and a 12 month high of $35.92. The firm has a market cap of $88,140.00, a price-to-earnings ratio of 25.34, a price-to-earnings-growth ratio of 3.44 and a beta of 0.76.

AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The firm had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.32 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. equities research analysts forecast that AstraZeneca plc will post 1.88 EPS for the current year.

AZN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upgraded shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Leerink Swann lifted their price target on shares of AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. Credit Suisse Group upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Finally, BMO Capital Markets set a $38.00 price target on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $34.20.

ILLEGAL ACTIVITY WARNING: “New England Research & Management Inc. Sells 9,400 Shares of AstraZeneca plc (AZN)” was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://transcriptdaily.com/2018/01/10/new-england-research-management-inc-sells-9400-shares-of-astrazeneca-plc-azn.html.

AstraZeneca Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply